



## Onset of Mania by Vitamin B12 Injection in a 52-Year Old Patient with Refractory and Resistant Depression

Valentina Artoonian; MD<sup>1</sup>, Vajihah Aghamollai; MD<sup>2</sup>, Azadeh Nadjarzadeh; PhD<sup>3,4</sup> & Reza Bidaki; MD<sup>\*5,6</sup>

<sup>1</sup> Department of Psychiatry, Fellowship in Psychotherapy, Tehran University of Medical Sciences, Tehran, Iran; <sup>2</sup> Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran; <sup>3</sup> Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; <sup>4</sup> Nutrition and Food Security Research Center, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran <sup>5</sup> Research Center of Addiction and Behavioral Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; <sup>6</sup> Fellowship in Neuropsychiatry, Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

### ARTICLE INFO

#### CASE REPORT

##### Article history:

Received: 10 Jul 2021  
Revised: 28 Dec 2021  
Accepted: 28 Dec 2021

##### \*Corresponding author

Reza.Bidaki111@gmail.com  
Research Center of Addiction and Behavioral Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Postal code: 8991683316

Tel: +98 353 2632004

### ABSTRACT

Vitamin B<sub>12</sub> affects and modify the function of multiple organ systems. Its deficiency may cause psychiatric symptoms in addition to hematologic, gastrointestinal, and neurologic manifestations. The present case study aims to report a patient with vitamin B<sub>12</sub> deficiency who coexisted with resistant and persistent depression, and experienced mania phase after the replacement of vitamin B<sub>12</sub>. For a patient with refractory and resistant depression and evidence or a risk factor for vitamin B<sub>12</sub> deficiency, it is required to check plasma levels and monitor psychiatric symptoms during vitamin B<sub>12</sub> supplementation. There are some manifestations of B<sub>12</sub> deficiency including bipolar disorder, mood lability, irritability, and psychosis due to deficiency but we didn't find case report about induce of psychiatric presentation follow correction of vitamin B<sub>12</sub> deficiency.

**Keywords:** Refractory depression; Bipolar disorder; Vitamin B<sub>12</sub> deficiency

### Introduction

Pharmacological induced hypomania or mania should be carefully considered after use of a medicinal agent and mood disorder is suggested according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) (Terao and Tanaka, 2014). Although solitary case reports are not reliable in general, and evidence must be sought from large series and systematic reviews of treated patients

matched with control groups, every precise case presentation can contribute new insights and cues for science development.

Vitamin B<sub>12</sub> or cobalamin, is one of the essential vitamins, affecting various systems of the body. Vitamin B<sub>12</sub> deficiency leads to psychiatric symptoms and is parallel with hematologic, gastrointestinal, and neurologic manifestations {Murray, 2012 #13}.

This paper should be cited as: Artoonian V, Aghamolae V, Nadjarzadeh A, Bidaki R. Onset of Mania by Vitamin B12 Injection in a 52-Year Old Patient with Refractory and Resistant Depression. Journal of Nutrition and Food Security (JNFS), 2023; 8(2): 158-162.

Both vitamin B<sub>12</sub> and folic acid play roles as cofactors in the neurotransmitter synthesis like serotonin and norepinephrine (Hutto, 1997). Vitamin B<sub>12</sub> deficiency changes neurotransmitters rate and can predispose to mood disorders (Deana et al., 1977).

This case study aims to report on a patient with vitamin B<sub>12</sub> deficiency and resistant depression, who experienced mania phase after vitamin B<sub>12</sub> replacement. The researchers did not find any similar cases. There are some cases with B<sub>12</sub> deficiency that showed manifestations of bipolar disorder, mood lability, irritability, and psychosis due to deficiency but we didn't find psychiatric presentation follow correction of vitamin B<sub>12</sub> deficiency.

### Case presentation

A 52-year old married, right handed woman with a non-vegetarian diet with the diagnosis of Major Depressive Disorder, despite taking medicine (Sertraline 100 mg/day and Trazodone 50 mg/day), experienced exacerbation in her symptoms. Gradually, paranoia and persecutory overvalue idea were added and increasing Sertraline dose up to 150 mg/day and adding Perphenazine 4 mg/day, were not effective. Moreover, speech volume and rate were reduced and she became progressively isolated from her family and peers. Her attention to personal health care was decreased. Finally, symptoms of oscillatory cognitive disturbance and generalized weakness were recognized. According to these symptoms, she was referred to a neurologist with complaints of "insomnia, depression, anhedonia, agitation, psychomotor retardation, persecutory delusion, generalized weakness, oppositional states, orolinguomandibular dyskinesia, and progression of cognitive impairment without parkinsonism symptoms. In the mental status examination and evaluation showed impaired attention, concentration, reduced working and short-term memory. Her Montreal Cognitive Assessment screening test (MOCA) core was 22.

She was psychotic; therefore, Tab. Quetiapine 25 mg was prescribed. However, worry and

agitation were exacerbated. Her daughter confirmed that these complaints had been obvious and started in the past year. Speech volume and rate had reduced, and she had become progressively isolated from her family and peers. According to previous psychiatric history, she suffered from depression with onset from past 8 years, with a pattern of recurrence and resistance in during last year. She was admitted in psychiatry ward and discharged after full remission of disorder. Drugs included Tab. Sertraline 150 mg/day and Tab. Lorazepam 1 mg at night, anti-diabetic agents (Diabetes known case) and Tab. Cabergoline (because of hypophysis micro adenoma hyper prolactinemia) at that time. In the next episode, she experienced depressive symptoms again. The psychiatrist added the previous medication with Tab. Bupropione. She did not show a suitable response to treatment and was admitted again. In this episode she had suicidal thoughts. She was prescribed Sertraline 200 mg/day, Bupropion 150 mg/day and Trazodone 25 mg/day and was discharged with partially remission. She passed another two years with this combination of drugs. In her third episode, she was visited by psychiatrist out of our center and was diagnosed with bipolar disorder and was prescribed with Lithium Carbonate which she could not tolerate it due to its side effects. Therefore, she came back to our center, and because there were not found any significant symptoms of bipolar disorder, she was diagnosed depression disorder and was prescribed by Sertraline 100mg/day and Trazodone 50mg/day again and her symptoms got partially remission for another one year.

About premorbid personality, there were extrovert, euthymic, and openness traits and there aren't history of major psychiatric diagnosis include bipolar spectrum, psychotic disorder or postpartum depression. Finally, during the past year, she has used Tab. Sertraline 150 mg/day for treatment of depression, but it has not elevated her mood.

She had a history of refractory depressive disorder and was resistant to treatment with

psychotic features at the age of 44 years.

Previous medical history included diabetes mellitus, hypothyroidism, hypophysis micro adenoma, and hyper prolactinemia. She did not have GI upset, history of specific dietary regimen and tablet (Metformine and H<sub>2</sub> blockers). Drugs including Tab. Cabergoline and Tab. Donepezil (5 mg/day) were started because of cognitive impairment and hyper prolactinemia by another physician. However, it was suggested that they stop using these medications because that vascular cognitive impairment was more possible diagnosis about this case. Brain imaging showed medial temporal atrophy (MTA), stage 2 based on Shelton score.

Considering some neurologic symptoms and signs like paresthesia and thyroid abnormality, levels of B<sub>12</sub> and prolactin were assessed. In last laboratory findings, she had low vitamin B<sub>12</sub> level (109 pg/ml) and plasma prolactin was 54µg/l and MCV was 84 fl. Therefore, Vitamin B<sub>12</sub> as IM injection was prescribed. After 4 days, she showed an irritable mood and after follow up it was onset of manic episode. Therefore, Vitamin B<sub>12</sub> as IM injection was prescribed. After 4 days, she showed an irritable mood and in follow ups it was onset of manic episode. Therefore, we started Tab. Sodium Valproate 200 mg BID, Tab. Quetiapine 50 mg twice a day. After one month by raising the dose of sodium Valproate up to 800mg/day and Quetiapine up to 250 mg/day, her mania symptoms disappeared. Moreover, her neurological symptoms like orolingualmandibular dyskinesia and cognitive state was significantly got better 3 months after vitamin B<sub>12</sub> supplementation. In a sense, her MOCA score was 25 at that time.

### Ethical considerations

Written informed consent was taken from the caregiver for publication of this case study. This case was presented in ethical committee of Roozbeh hospital, Tehran and approved with code number IR798933 in Feb 2022.

### Discussion

Although adequate vitamin B<sub>12</sub> concentration and status is essential in all human life, it seems

more important in some conditions such as elderly people, women in childbearing ages, and even patients with psychiatric disorder. The patient was middle-aged with atypical and resistant depression, which was nearly late onset, and the medication changed after taking vitamin B<sub>12</sub>. Therefore, she was a patient with bipolar disorder type III. It is known that the prevalence of bipolar disorder is declined in the elderly (Depp and Jeste, 2004). Therefore, it requires medical evaluation due to the underlying disease.

Therefore, if a new case of bipolar disorder, atypical depression, and resistant depression at middle or old age refer, complete assessment will be necessary because of some organic problems like various type of deficiencies. The level of B<sub>12</sub> should be assessed based on the history of atypical psychiatric symptoms, treatment-resistant depressive disorders even without presence of risk factors for nutritional deficiency such as alcoholism, elderly age, Tab. Metformin, PPI, H<sub>2</sub> blockers, malabsorption, GI surgery or vegetarian diet.

Although mechanism of depression due to vitamin B<sub>12</sub> deficiency is determined, the effect of vitamin B<sub>12</sub> on the treatment of mania is unclear. Neurological impairments such as neuropathy, myelopathy, memory impairment, dementia and brain atrophy may happen in cases of low B<sub>12</sub> status (Vogiatzoglou *et al.*, 2009). Except for brain atrophy and memory impairment, the patient did not have any problems after vitamin B<sub>12</sub> replacement and mood disorder management. Some studies have shown that metformin and the duration of consumption is associated with level of vitamin B<sub>12</sub> (Beulens *et al.*, 2015, Ko *et al.*, 2014).

In a case study, a woman who suffered from psychotic depression did not respond to conventional therapy but resolved significantly after replacement of vitamin B<sub>12</sub> (Milanlioğlu and Investigations, 2011). Vitamin B<sub>12</sub> deficiency has shown a significant relationship with chronic recurrent depression especially in a oxidative stress condition (van de Lagemaat *et al.*, 2019).

The studied patient had a dramatically response as euphoric mood and manic state. Dose and

prescription of vitamin B<sub>12</sub>, patient's characteristic, type of depression, brain reserve, and atrophy might be important for type of therapeutic response as non-responder, euthymic, elevated or euphoric mood and even psychosis.

Probiotic-containing fermented foods can change the microbiome and increase the bio-availability of mood-regulating B vitamins crucial to neurotransmitter production. Vitamin D deficiency results in increasing pro-inflammatory cytokines and disrupts mitochondrial function and monoamine production. Magnesium, Vitamin D, and B vitamins deficiency correlate with depression severity. Deficiency of folate also may lead to treatment-resistant depression (Simkin and Arnold, 2020). A mixture of EPA and docosahexaenoic acid has been reported to improve depression and the course of illness in bipolar disorder (Bozzatello *et al.*, 2016).

In the elderly with low vitamin B<sub>12</sub> plasma level, elevated serum folate concentration was related to acceleration of cognitive decline, but in people with normal vitamin B<sub>12</sub>, high serum folate level was shown to be protective against cognitive decline (Morris *et al.*, 2007). Folate concentration was not evaluated in this patient. However, it can be mentioned that this condition can affect mood status.

Studies with prospective design, large case series, clinical trial, and systematic review studies which focused on vitamin deficiency or augmentation and outcomes are needed for understanding the role of this vitamin the etiology of similar diseases.

### Conclusion

Patients with refractory and resistant depressive disorder, especially middle-aged and elderly, need for checking and replace Vitamin B<sub>12</sub> with monitoring of psychiatric symptoms.

### Acknowledgement

Thanks are owed to the patient's family for participation in this case study.

### Conflicts of interest

The authors declare that they have no conflict of interest.

### Authors' contributions

Artoonian V and Aghamollai V interviewed the patient and collected data, Bidaki R wrote primary draft and discussed about it, and Nadjarzadeh A and Bidaki R critically revised and submitted it.

### References

- Beulens JW, Hart HE, Kuijs R, Kooijman-Buiting AM & Rutten GE** 2015. Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin. *Acta diabetologica*. **52** (1): 47-53.
- Bozzatello P, Brignolo E, De Grandi E & Bellino S** 2016. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. *Journal of clinical medicine*. **5** (8): 67.
- Deana R, Vincenti E & Deana AD** 1977. Levels of neurotransmitters in brain of vitamin B<sub>12</sub> deficient rats. *International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernährungsforschung. Journal international de vitaminologie et de nutrition*. **47** (2): 119-122.
- Depp CA & Jeste DV** 2004. Bipolar disorder in older adults: a critical review. *Bipolar disorders*. **6** (5): 343-367.
- Hutto BR** 1997. Folate and cobalamin in psychiatric illness. *Comprehensive psychiatry*. **38** (6): 305-314.
- Ko SH, et al.** 2014. Association of vitamin B<sub>12</sub> deficiency and metformin use in patients with type 2 diabetes. *J Korean Med Sci*. **29** (7): 965-972.
- Milanhoğlu AJJoC & Investigations E** 2011. Vitamin B<sub>12</sub> deficiency and depression. *JCEI*. **2** (4): 455-456.
- Morris MS, Jacques PF, Rosenberg IH & Selhub J** 2007. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. *The American journal of clinical nutrition*. **85** (1): 193-200.
- Simkin DR & Arnold LE** 2020. The Roles of Inflammation, Oxidative Stress and the Gut-Brain Axis in Treatment Refractory Depression

in Youth: Complementary and Integrative Medicine Interventions. *OBM Integrative and complementary medicine*. **5 (4)**: 1-25.

**Terao T & Tanaka T** 2014. Antidepressant-induced mania or hypomania in DSM-5. *Psychopharmacology*. **231 (1)**: 315.

**van de Lagemaat EE, de Groot L & van den Heuvel E** 2019. Vitamin B12 in Relation to

Oxidative Stress: A Systematic Review. *Nutrients*. **11 (2)**: 482.

**Vogiatzoglou A, et al.** 2009. Dietary sources of vitamin B-12 and their association with plasma vitamin B-12 concentrations in the general population: the Hordaland Homocysteine Study. *American journal of clinical nutrition*. **89 (4)**: 1078-1087.